Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease. According to the insights of surveyed U.S. and European pulmonologists, greater reduction in exacerbation rate and greater improvement in quality of life are key areas of unmet need for moderate to severe asthma. Furthermore, novel agents with strong efficacy in reducing the rate of exacerbations will have considerable influence on physician prescribing decisions as competition among pharmacological agents rapidly increases in the moderate to severe asthma market.

Table of contents

  • Asthma - Unmet Need - Detailed, Expanded Analysis (Moderate To Severe Asthma)
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Moderate to Severe Asthma
        • Efficacy
        • Importance of Efficacy Attributes to Prescribing Decisions in Moderate to Severe Asthma — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Moderate to Severe Asthma — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Moderate to Severe Asthma — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Moderate to Severe Asthma — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Moderate to Severe Asthma — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Moderate to Severe Asthma — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Moderate to Severe Asthma — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Moderate to Severe Asthma — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Moderate to Severe Asthma
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Moderate to Severe Asthma — United States
        • Overall Performance of Key Therapies for Moderate to Severe Asthma — Europe
        • Relative Performance of Key Therapies for Moderate to Severe Asthma Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for Moderate to Severe Asthma Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for Moderate to Severe Asthma Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for Moderate to Severe Asthma Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for Moderate to Severe Asthma Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for Moderate to Severe Asthma Across Select Convenience of Administration Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Pulmonologists' Satisfaction With the Performance of Key Therapies for Moderate to Severe Asthma on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Pulmonologists' Satisfaction With the Performance of Key Therapies for Moderate to Severe Asthma on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in Moderate to Severe Asthma
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Moderate to Severe Asthma — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Moderate to Severe Asthma — Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Moderate to Severe Asthma — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Moderate to Severe Asthma — Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Moderate to Severe Asthma — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Moderate to Severe Asthma — Europe
      • Unmet Need in Moderate to Severe Asthma and Related Indications
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need in Moderate to Severe Asthma and Related Indications — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need in Moderate to Severe Asthma and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Moderate to Severe Asthma Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent Capable of Substantially Reducing Exacerbation Rates in Moderate to Severe Asthma Patients
        • Opportunity: A New Therapy with Efficacy in Reducing OCS Use in Moderate to Severe Asthma
        • Opportunity: A New Agent with Efficacy Demonstrated in a Broad Patient Population Regardless of Patient Phenotype
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Moderate to Severe Asthma Target Product Profile: Attribute Importance
        • Moderate to Severe Asthma Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Moderate to Severe Asthma Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Moderate to Severe Asthma Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Moderate to Severe Asthma Market Simulations: Target Product Profiles Included in Scenario 1
        • Moderate to Severe Asthma Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Moderate to Severe Asthma Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Moderate to Severe Asthma Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Eun-Jin Yang, PhD

Eun-Jin Yang, Ph.D. is a senior business insights analyst at Decision Resources Group. She has authored market research reports analyzing physician, payer, and market trends in asthma, COPD, Lupus, and other autoimmune diseases.

Her prior experience includes publishing pharmaceutical and biotechnology company-focused industry research articles as a cofounding analyst in the Harvard Biotechnology Club and helping to commercialize inventions in various therapeutic areas from Massachusetts General Hospital and Brigham and Women’s Hospital. She finished her postdoctoral fellowships at Boston Children’s Hospital, Harvard University, and Columbia University. She received her Ph.D. at the University of Texas at Austin.


Related Reports

Asthma | Disease Landscape and Forecast | G7 | 2020

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva), oral dr...

View Details

Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)

The asthma market in the EU5 is highly competitive. Ma...

View Details

Asthma - Landscape & Forecast - Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

View Details